ABO blood group does not influence Child‐Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts. (17th January 2022)

• Record Type: Journal Article
• Authors: Ollivier‐Hourmand, Isabelle; Repesse, Yohann; Nahon, Pierre; Chaffaut, Cendrine; Dao, Thông; Nguyen, Thi Thu Nga; Marcellin, Patrick; Roulot, Dominique; De Ledinghen, Victor; Pol, Stanislas; Guyader, Dominique; Archambeaud, Isabelle; Zoulim, Fabien; Oberti, Frédéric; Tran, Albert; Bronowicki, Jean‐Pierre; D'Alteroche, Louis; Ouzan, Denis; Peron, Jean‐Marie; Zarski, Jean‐Pierre; Bourliere, Marc; Larrey, Dominique; Louvet, Alexandre; Cales, Paul; Abergel, Armand; Mathurin, Philippe; Mallat, Ariane; Blanc, Jean‐Frederic; Nguyen‐Khac, Eric; Riachi, Ghassan; Alric, Laurent; Serfaty, Lawrence; Antonini, Teresa; Moreno, Christophe; Attali, Pierre; Thabut, Dominique; Pilette, Christophe; Grange, Jean‐Didier; Silvain, Christine; Carbonell, Nicolas; Bernard‐Chabert, Brigitte; Goria, Odile; Wartelle, Claire; Moirand, Romain; Christidis, Christos; Perlemuter, Gabriel; Ozenne, Violaine; Henrion, Jean; Hillaire, Sophie; Di Martino, Vincent; Amiot, Xavier; Sutton, Angela; Barget, Nathalie; Chevret, Sylvie; Ganne‐Carrie, Nathalie;
• Is Part Of: Liver international. Volume 42:Number 6(2022)
• Page Start: 1386
• Page End: 1400
• Publication Date: 2022-01-17
• Subjects: ABO blood group -- alcoholic cirrhosis -- Child‐Pugh A cirrhosis -- non‐malignant portal vein thrombosis -- outcome -- viral cirrhosis; Liver -- Periodicals; Liver -- Diseases -- Periodicals; 616.362
• DOI: 10.1111/liv.15159
• Languages: English
• ISSNs: 1478-3223

Abstract

Abstract: Background and aims: Non‐O blood group promotes deep vein thrombosis and liver fibrosis in both general population and hepatitis C. We aimed to evaluate the influence of Non‐O group on the outcome of Child‐Pugh A cirrhotic patients. Methods: We used two prospective cohorts of Child‐Pugh A cirrhosis due to either alcohol or viral hepatitis. Primary end point was the cumulated incidence of 'Decompensation' at 3 years, defined as the occurrence of ascites, hydrothorax, encephalopathy, gastrointestinal bleeding related to portal hypertension, or bilirubin >45 μmol/L. Secondary end points were the cumulated incidences of (1) 'Disease Progression' including a « decompensation» or « the occurrence of one or more parameters » among: prothrombin time (PT) <45%, albumin <28 g/L, Child‐Pugh worsening (B or C vs A or B, C vs B), hepatorenal syndrome, and hepato‐pulmonary syndrome, (2) other events such as non‐malignant portal vein thrombosis (nmPVT), and (3) overall survival. Results: Patients (n = 1789; 59.9% Non‐O group; 40.1% group O) were followed during a median of 65.4 months. At 3 years cumulated incidence of Decompensation was 8.3% in Non‐O group and 7.2% in group O ( P = .27). Cumulated incidence of Disease Progression was 20.7% in Non‐O group and 18.9% in group O ( P = .26). Cumulated incidence of nmPVT was 2.7% in Non‐O group and 2.8% in group O ( P = .05). At 3 years overall survival was 92.4% in Non‐O group and 93.4% in group O ( P = 1). Conclusion: Non‐O group does not influence disease outcome in Child‐Pugh A cirrhotic patients. Clinicals trial number NCT03342170.